Tenaya Therapeutics, Inc.
NASDAQ:TNYABiotechnology
-$0.00 today
- Market cap
- $69.95M
- Beta
- 2.82
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$0.54
Volume 2.77M
Average 3.79M
TNYA Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Tenaya Therapeutics, Inc.NASDAQ: TNYA
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit turns negative
Q1 FY2026 gross profit was -$1.54M, compared with $0 a year earlier. Trailing-twelve-month gross profit was $326K.
Context
- Gross profit grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly gross profit holds near -$1.54M or moves back toward the trailing-twelve-month quarterly average of $81.5K.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- (8.44M) USD
- Year-over-year change
- +0.4%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (8.44M) | +0.4% |
| FY2024 | 2024-12-31 | (8.47M) | +2.5% |
| FY2023 | 2023-12-31 | (8.69M) | +0.3% |
| FY2022 | 2022-12-31 | (8.71M) | -116.5% |
| FY2021 | 2021-12-31 | (4.03M) | — |
Gross Profit vs competitors
How TNYA compares with its peers on the latest reported figures
- TNYA's LTM Mar 2026 gross profit of $326K is the 7th highest of the 11 companies compared; the peer median is $6.92M.
- Its year-over-year change of +115.4% is the 4th highest of 10, against a peer median of +43.5%.
- Gross profit amounts to 144.9% of revenue for TNYA, versus a peer median of 92.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $68M | +5.5% | -11.0% | 98.3% | |
| LTM Mar 2026 | $16.33M | +133.3% | — | 97.7% | |
| LTM Mar 2026 | $13.83M | — | — | 99.8% | |
| LTM Mar 2026 | $9.26M | +117.7% | -9.7% | 82.6% | |
| LTM Mar 2026 | $7.55M | +1072.9% | +64.5% | 51.9% | |
| LTM Mar 2026 | $6.28M | -73.3% | +12.8% | 22.3% | |
| LTM Mar 2026 | $326K | +115.4% | — | 144.9% | |
| LTM Mar 2026 | -$793.21K | -354.2% | — | — | |
| LTM Mar 2026 | -$6.32M | +43.5% | — | — | |
| LTM Mar 2026 | -$15.09M | -917.5% | — | 748.5% | |
| LTM Mar 2026 | -$31.63M | +46.9% | — | 86.7% | |
| Peer median (excluding TNYA) | $6.92M | +43.5% | +1.5% | 92.2% | |
Competitors are the stored peer set for TNYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 4.03M | 8.71M | 8.69M | 8.47M | 8.44M |
| Gross Profit | (4.03M) | (8.71M) | (8.69M) | (8.47M) | (8.44M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 54.39M | 94.54M | 98.04M | 86.74M | 68.61M |
| Selling, General & Admin | 14.39M | 22.37M | 24.47M | 20.74M | 24.72M |
| Operating Expenses | 68.78M | 116.91M | 122.51M | 107.48M | 84.9M |
| Depreciation & Amortization | 4.03M | 8.71M | 8.69M | 8.47M | 8.44M |
| EBITDA | (68.7M) | (114.95M) | (115.4M) | (102.66M) | (82.16M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (72.81M) | (125.62M) | (131.19M) | (115.95M) | (93.33M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 108K | 1.95M | 7.06M | 4.74M | 2.68M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 85K | 1.96M | 7.11M | 4.82M | 2.73M |
| Income Before Tax | (72.72M) | (123.67M) | (124.08M) | (111.13M) | (90.6M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (72.72M) | (123.67M) | (124.08M) | (111.13M) | (90.6M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.69) | (2.76) | (1.68) | (1.31) | (0.59) |
| EPS (Diluted) | (1.69) | (2.76) | (1.68) | (1.31) | (0.59) |
| Weighted Avg Shares | 41.29M | 44.82M | 73.79M | 84.82M | 152.97M |
| Weighted Avg Shares (Diluted) | 41.29M | 44.82M | 73.79M | 84.82M | 152.97M |
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
Intrinsic Alpha fair value
Locked
Current Price
$0.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.